A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhancedin vitroanti-tumor activity
Authors:
- Zhiye QiuZQZhiye Qiu
- Shenqi WangSWShenqi Wang
- Lei ZhouLZLei Zhou
- Shengmin ZhangSZShengmin Zhang
- 6 October 2010
- journal article
- Published by IOP Publishing in Biomedical Materials
- Vol. 5 (6) , 065002
Abstract
The encapsulation of hydrophilic drug in polymeric nanoparticles with high loading remains a challenge due to the rapid penetration of the drug to the external aqueous phase. In order to improve the encapsulation efficiency of daunorubicin (DNR) in poly(D,L-lactic-co-glycolic acid (PLGA) and poly(D,L-lactic acid) (PDLLA) nanoparticles, we fabricated a series of DNR-loaded nanoparticles using a modified double-emulsion solvent evaporation/diffusion method, which introduced a partially water-soluble organic solvent into the particle formation. The influence of various preparation parameters was investigated systematically, such as the ratio of organic solvent, the type of surfactant, the type of polymers and the molecular weight. Results showed that regular spherical PLGA nanoparticles with diameters of 200-300 nm could be produced with a remarkably high DNR encapsulation efficiency (>80%) and loading (6.5% (w/w)). Upon encapsulation, the sustained release of DNR could be controlled over 2 weeks. The results of FT-IR and DSC analysis indicated that the encapsulated DNR in polymeric nanoparticles was inclusion, not absorption. Furthermore, optimized DNR/PLGA nanoparticles showed a significant enhancement of cellular uptake, higher cytotoxicity against HL-60 cells compared with free DNR. These results were potentially useful for the nanoparticle formulation of hydrophilic chemotherapeutic drugs that require efficient delivery to cancer cells as well as sustained release at the specific site.Keywords
This publication has 47 references indexed in Scilit:
- Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistanceBiomaterials, 2010
- Economic burden of acute myeloid leukemia: a literature reviewCancer Treatment Reviews, 2004
- Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project ExperienceJournal of Clinical Oncology, 2003
- Biodegradable nanoparticles for drug delivery and targetingCurrent Opinion in Solid State and Materials Science, 2002
- A daunorubicin β-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapyTetrahedron Letters, 2000
- Development of daunorubicin resistance in tumour cells by induction of carbonyl reductionBiochemical Pharmacology, 2000
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Biodegradation and biocompatibility of PLA and PLGA microspheresAdvanced Drug Delivery Reviews, 1997
- Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development1This manuscript is dedicated to the memory of Dr. Michael J. Cronin. Dr. Cronin was a brilliant endocrine scientist with an incredible ability to objectively evaluate any problem, no matter how complex. His spirit and knowledge contributed to the success of the work described herein and his wisdom continues to guide those of us fortunate enough to have known him.1Advanced Drug Delivery Reviews, 1997